Acurx Narrows Q3 Loss, But Going Concern Doubts Persist

Ticker: ACXP · Form: 10-Q · Filed: Nov 12, 2025 · CIK: 1736243

Sentiment: bearish

Topics: Biotechnology, Pharmaceuticals, Going Concern, Net Loss, Cash Burn, Equity Financing, Clinical Stage

TL;DR

**ACXP is burning cash and explicitly states it can't survive 12 months without more funding, making it a high-risk bet despite narrower losses.**

AI Summary

Acurx Pharmaceuticals, Inc. (ACXP) reported a net loss of $1,992,790 for the three months ended September 30, 2025, an improvement from a net loss of $2,821,597 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $6,388,262, significantly lower than the $11,321,312 loss in the prior year. Research and Development expenses decreased substantially, from $4,578,777 in the nine months ended September 30, 2024, to $1,552,699 in the same period of 2025. General and Administrative expenses also saw a reduction, from $6,750,679 to $4,922,168 year-over-year for the nine-month period. The company's cash balance increased to $5,906,802 as of September 30, 2025, up from $3,706,713 at December 31, 2024, primarily due to financing activities, including $2,480,553 from warrant exercises and $2,334,945 from an equity line of credit. Despite these improvements, management explicitly stated that the current cash balance is insufficient to meet anticipated cash requirements for at least 12 months, raising substantial doubt about the company's ability to continue as a going concern.

Why It Matters

Acurx Pharmaceuticals' continued net losses and explicit 'going concern' warning are critical for investors, signaling high financial risk and potential dilution from future equity raises. The significant reduction in R&D and G&A expenses, while improving the bottom line, could also indicate a slowdown in critical drug development for its lead candidate, ibezapolstat, which targets C. difficile infections. This financial instability could impact the company's ability to compete with larger pharmaceutical firms in the antibiotic space and secure necessary regulatory approvals, ultimately affecting patients awaiting novel treatments and employees' job security. The reliance on equity financing, including a recent $12.0 million equity line of credit, suggests a continuous need for capital, which could further depress share value.

Risk Assessment

Risk Level: high — The company explicitly states, "Management believes that the Company will continue to incur losses for the foreseeable future and will need additional resources to sustain its operations until it can achieve profitability and positive cash flows, if ever." Furthermore, it notes that its cash balance of approximately $5.9 million as of September 30, 2025, "will not be sufficient to meet its anticipated cash requirements for at least 12 months," raising substantial doubt about its ability to continue as a going concern.

Analyst Insight

Investors should exercise extreme caution and consider avoiding ACXP given the explicit going concern warning and continuous reliance on dilutive equity financing. Those holding shares should evaluate their risk tolerance and consider reducing exposure, as further capital raises are highly probable and could lead to significant share price depreciation.

Financial Highlights

debt To Equity
0.68
revenue
$0
operating Margin
N/A
total Assets
$6,105,211
total Debt
$2,468,175
net Income
($1,992,790)
eps
($1.23)
gross Margin
N/A
cash Position
$5,906,802
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Acurx Pharmaceuticals' current cash position as of September 30, 2025?

Acurx Pharmaceuticals, Inc. reported a cash balance of $5,906,802 as of September 30, 2025. This represents an increase from $3,706,713 at December 31, 2024, primarily due to recent financing activities.

Did Acurx Pharmaceuticals' net loss improve in the latest quarter?

Yes, Acurx Pharmaceuticals' net loss for the three months ended September 30, 2025, was $1,992,790, which is an improvement compared to the net loss of $2,821,597 for the same period in 2024.

What are the key reasons for the decrease in Acurx Pharmaceuticals' operating expenses?

For the nine months ended September 30, 2025, Research and Development expenses decreased to $1,552,699 from $4,578,777 in the prior year, and General and Administrative expenses decreased to $4,922,168 from $6,750,679. These reductions contributed to the overall decrease in operating expenses.

What is the primary concern regarding Acurx Pharmaceuticals' ability to continue operations?

The primary concern is the company's 'going concern' warning. Management explicitly stated that the cash balance of approximately $5.9 million as of September 30, 2025, will not be sufficient to meet anticipated cash requirements for at least 12 months, raising substantial doubt about its ability to continue as a going concern.

How has Acurx Pharmaceuticals been funding its operations recently?

Acurx Pharmaceuticals has been funding its operations through various equity financings. In 2025, this included $2,480,553 from warrant exercises, $2,334,945 from an equity line of credit purchase agreement, $889,420 from a March Registered Direct Offering, and $2,099,253 from a January Registered Direct Offering.

What is ibezapolstat and its significance for Acurx Pharmaceuticals?

Ibezapolstat (formerly GLS362E and ACX-362E) is Acurx Pharmaceuticals' lead antibiotic product candidate. It targets the treatment of C. difficile infections (CDI), representing the company's primary focus in developing novel antibiotics.

What is the weighted average common shares outstanding for Acurx Pharmaceuticals?

For the three months ended September 30, 2025, the weighted average common shares outstanding for Acurx Pharmaceuticals was 1,625,805. For the nine months ended September 30, 2025, it was 1,275,592.

What is the impact of the COVID-19 pandemic on Acurx Pharmaceuticals?

The company states that its clinical trial operations were directly and indirectly adversely impacted by the COVID-19 pandemic and could continue to be affected. The extent of the effect on operational and financial performance depends on future developments, including duration, spread, and intensity of the pandemic, as well as economic effects like inflation and supply chain disruptions.

What is Acurx Pharmaceuticals' strategy to address its funding needs?

Management plans to seek additional equity financing and grant funding to sustain its operations. However, there is no assurance that such financing and funding will be available on acceptable terms, or at all, given the company's current financial position.

How many shares of common stock were outstanding for Acurx Pharmaceuticals as of November 11, 2025?

As of November 11, 2025, there were 2,085,363 shares of common stock, $0.001 par value, issued and outstanding for Acurx Pharmaceuticals, Inc.

Risk Factors

Industry Context

Acurx Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on developing novel antibiotics to combat serious bacterial infections. The sector is characterized by long development cycles, significant R&D investment, and stringent regulatory requirements for drug approval. Emerging challenges include antibiotic resistance, which drives demand for new treatments, but also necessitates innovative approaches and substantial clinical validation.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Acurx is subject to rigorous oversight by regulatory bodies like the FDA. The development and approval process for new antibiotics is lengthy, costly, and uncertain. Any delays or failures in clinical trials or regulatory submissions could significantly impact the company's financial condition and future prospects.

What Investors Should Do

  1. Monitor Cash Burn and Future Financing
  2. Evaluate R&D Progress and Clinical Trial Data
  3. Assess Management's Going Concern Disclosure
  4. Analyze Expense Reduction Effectiveness

Key Dates

Glossary

Accumulated Deficit
The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company has not yet achieved profitability, with a deficit of $73,710,218 as of September 30, 2025.)
Going Concern
An accounting assumption that a company will continue to operate for the foreseeable future. If doubt exists, it must be disclosed. (Management has explicitly stated substantial doubt about the company's ability to continue as a going concern due to insufficient cash.)
Clinical Stage Biopharmaceutical Company
A company focused on developing new drugs that are currently in human trials (clinical trials) but have not yet received regulatory approval for sale. (Acurx Pharmaceuticals is in this stage, meaning significant R&D expenses and regulatory hurdles lie ahead.)
Equity Line of Credit
An agreement where a company can sell shares of its stock to an investor at its discretion, up to a certain amount. (Acurx utilized an equity line of credit, raising $2,334,945, to supplement its cash position.)
Warrant Exercise
The act of a holder of a stock warrant buying the underlying stock at a specified price before the warrant expires. (Acurx received $2,480,553 from warrant exercises, contributing to its cash increase.)
Par Value
A nominal value assigned to a share of stock by the company's charter, often very low for common stock. (The common stock has a par value of $0.001 per share, with 1,800,299 shares issued and outstanding as of September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year, Acurx Pharmaceuticals has significantly reduced its net loss for both the three-month period (from $2,821,597 to $1,992,790) and the nine-month period (from $11,321,312 to $6,388,262). This improvement is largely driven by substantial decreases in Research and Development expenses (down from $4,578,777 to $1,552,699 for the nine months) and General and Administrative expenses (down from $6,750,679 to $4,922,168). The company's cash position has improved to $5,906,802 from $3,706,713, primarily due to financing activities. However, a new critical risk factor has emerged regarding substantial doubt about the company's ability to continue as a going concern.

Filing Stats: 4,410 words · 18 min read · ~15 pages · Grade level 17.3 · Accepted 2025-11-12 07:00:44

Key Financial Figures

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II - OTHER INFORMATION 30 Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 65 Item 3. Defaults Upon Senior Securities 65 Item 4. Mine Safety Disclosure 65 Item 5. Other Information 65 Item 6. Exhibits 66

Signatures

Signatures 67 Certificates 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ("Quarterly Report") and certain information incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In this Quarterly Report, we refer to Acurx Pharmaceuticals, Inc., together with its subsidiary, as the "Company," "we," "our" or "us." All statements other than statements of historical facts contained herein, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect" or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A "Risk Factors." In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances included herein may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our ability to obtain and maintain regulatory approval of ibe

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

CONDENSED INTERIM FINANCIAL STATEMENTS

ITEM 1. CONDENSED INTERIM FINANCIAL STATEMENTS. ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM BALANCE SHEETS September 30, December 31, 2025 2024 (unaudited) (Note 2) ASSETS CURRENT ASSETS Cash $ 5,906,802 $ 3,706,713 Other Receivable 40,208 51,127 Prepaid Expenses 158,201 100,123 TOTAL ASSETS $ 6,105,211 $ 3,857,963 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts Payable and Accrued Expenses $ 2,468,175 $ 3,242,842 TOTAL CURRENT LIABILITIES 2,468,175 3,242,842 TOTAL LIABILITIES 2,468,175 3,242,842 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY Common Stock; $ .001 par value, 250,000,000 shares authorized, 1,800,299 shares issued and outstanding at September 30, 2025 and 200,000,000 shares authorized, 851,534 shares issued and outstanding at December 31, 2024 1,800 852 Additional Paid-In Capital 77,345,454 67,936,225 Accumulated Deficit ( 73,710,218 ) ( 67,321,956 ) TOTAL SHAREHOLDERS' EQUITY 3,637,036 615,121 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 6,105,211 $ 3,857,963 See accompanying notes to condensed interim financial statements. 5 Table of Contents ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM STATEMENTS OF OPERATIONS Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 (unaudited) (unaudited) (unaudited) (unaudited) OPERATING EXPENSES Research and Development $ 429,691 $ 1,198,184 $ 1,552,699 $ 4,578,777 General and Administrative 1,599,010 1,628,414 4,922,168 6,750,679 TOTAL OPERATING EXPENSES 2,028,701 2,826,598 6,474,867 11,329,456 OPERATING LOSS ( 2,028,701 ) ( 2,826,598 ) ( 6,474,867 ) ( 11,329,456 ) OTHER INCOME Interest Income 35,911 5,001 86,605 8,144 NET LOSS $ ( 1,992,790 ) $ ( 2,821,597 ) $ ( 6,388,262 ) $ ( 11,321,312 ) LOSS PER SHARE Basic and diluted net loss per common share $ ( 1.23 ) $ ( 3.45 ) $ ( 5.

Business

Business Acurx Pharmaceuticals, Inc., a Delaware corporation, formerly Acurx Pharmaceuticals, LLC (the "Company") is a clinical stage biopharmaceutical company formed in July 2017, with operations commencing in February 2018. The Company is focused on developing a novel class of antibiotics that address serious or life-threatening bacterial infections. In March 2020, the World Health Organization declared the outbreak of COVID- 19, a novel strain of coronavirus, a global pandemic. This outbreak caused major disruptions to businesses and markets worldwide as the virus continued to spread. Previously, the Company's clinical trial operations were directly and indirectly adversely impacted, and could continue to be directly and indirectly adversely impacted, by the COVID-19 pandemic. The extent of the effect on the Company's operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and governmental, regulatory and private sector responses, direct and indirect economic effects as a result of inflation, supply chain disruptions and labor shortages all of which are uncertain and difficult to predict. Although the Company is unable to estimate the financial effect of the pandemic, at this time, if the pandemic continues over a long period of time, it could have a material adverse effect on the Company's business, results of operations, financial condition, and cash flows. The unaudited condensed interim financial statements do not reflect any adjustments as a result of the pandemic. In February 2018, the Company purchased the active pharmaceutical ingredient, the intellectual property and other rights to an antibiotic product candidate known as GLS362E (renamed ACX-362E and now approved for non-proprietary name, ibezapolstat) (the "Asset") from GLSynthesis, Inc. The Company paid $ 110,174 in cash, along with granting 100,000 Class B Membership Interests, profits interests as defined in the op

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing